News | February 23, 2022
ACUITE upgrades ratings of Bal Pharma
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Appoints Dr Rafiq Hasan as CEO
he financing was significantly oversubscribed with high demand from both existing and new investors.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Subscribe To Our Newsletter & Stay Updated
